BioSpace News Archive

Eli Lilly continues to see positive news in its efforts to combat migraine headaches.

Two years after entering into a licensing relationship Canada-based Zymeworks Inc. and Japanese pharma giant Daiichi Sankyo have entered into a second licensing agreement to expand immuno-oncology research with bispecific antibodies.

The funds will be used to expand the pre-IND studies for its lead program AX09 in triple negative breast cancer (TNBC).

Proposals for Synergy Awards will be accepted online through September 17, 2018.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for RoclatanTM (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%.

Q1 2018 total sales of $2.9 million, up 473% year over year

Product revenues increased 60% to $1.6 million versus $1.0 million in the same prior year period

TIME-2b Clinical Trial of AKB-9778 in Patients with Diabetic Retinopathy Remains on Track

Investment will enable Surface to fund its development programs focused on FDA approval of its ocular disease drug candidates

Aldeyra is a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases